The eye area is one of the most studied regions in the face, and one of the most treated. And yet so many people who spend the most on it — worn down by looking tired even when they feel rested — are sold the wrong treatment for the actual problem.
This is not a warning against treating your under-eyes. Some treatments work very well for the right person. It is an explanation of why this small patch of skin is so much harder than the marketing suggests, why the "tired eye" you see in the mirror may not be what you think it is, and why this is the one area of the face where getting it wrong carries consequences far beyond a wasted appointment.
Why we fixate on the eyes
There is a reason under-eyes feel disproportionately important. When people look at a face, the eye region carries more of the signal for tiredness and age than any other feature. In eye-tracking studies, observers' gaze settles on the periorbital area first and longest when judging how rested or how old someone looks.¹
So the stakes feel high — and that is exactly the problem. High emotional stakes drive fast decisions, and fast decisions in this area tend to aim at the most visible symptom rather than its cause.
First — what you actually have
"Dark circles" is a description, not a diagnosis.
The medical literature is consistent on this: infraorbital darkening is multifactorial, and the visible result usually comes from more than one source at once.² ³ There are three main drivers, and they do not respond to the same treatments.
Pigment.
Excess melanin in the skin itself — often genetic, often worse with sun exposure, and common in people with allergies or eczema who rub the area, which leaves post-inflammatory pigmentation behind.² This is a brown problem.
Blood vessels.
The skin under the eye is the thinnest on the body. Where it is thin and translucent, the vascular bed and pooled blood show through as a bluish or purple cast. This is a colour problem of transparency, not of pigment.
One common and often-missed driver here is allergy: nasal congestion from hay fever slows venous drainage around the eye, so blood pools and the area darkens — the classic "allergic shiner," typically bluish-purple, on both sides, and worse in allergy season.ᵈ If that's the cause, treating the allergy does more than any eye cream.
Structure — the hollow.
As the midface ages, fat descends and the bony rim becomes more visible, creating a groove (the tear trough). What looks "dark" here is partly a shadow. This is a shape problem.
Most people have a combination — say, genuine pigment plus a hollow that casts a shadow over it. And this is where treatment goes wrong before it begins. A filler placed to correct a shadow does nothing for pigment, and if placed too superficially over thin skin, it adds its own bluish-grey haze — the Tyndall effect — making a vascular or pigmented circle look worse than before.²
A simple thing you can try at a mirror: gently stretch the skin sideways. If the darkness flattens out and fades, shadowing is likely contributing significantly. If it remains visible, pigment and/or vascular factors may also be involved. It is crude, and it is not a diagnosis — but it is more than most people consider before they are injected.
A pigment problem treated as a volume problem gets worse, not better.
The filler reflex
The belief: filler erases tired eyes. The reality: it addresses one of three causes — and it is the highest-stakes injection on the face.
If what you have is a genuine, isolated tear-trough hollow — good skin, not much pigment — hyaluronic acid filler can be an elegant fix. That much is true. The trouble is everything that surrounds that narrow case.
First, the cosmetic downside. Under-eye skin is thin and the area drains poorly, so this region is unusually prone to lumps, prolonged swelling (malar oedema), product migration, and the Tyndall haze. These are not catastrophes, but they are common, they last, and they are why so many "before/after" under-eye results look subtly off.
Then there is the rare, serious end. The angular artery runs through the tear-trough region, and it connects — through a network of anastomoses — to the ophthalmic artery, which supplies the eye.⁴
If filler is accidentally injected into a vessel, it can travel backwards into that supply and block it. Vascular occlusion serious enough to threaten vision is rare; published incidence estimates vary, but every major review describes it as an uncommon event.⁵
The outcomes when filler does reach the eye, however, are not minor. In the most comprehensive review to date — a century of published blindness cases — of those with reported visual outcomes, roughly 68% had no recovery of vision, about 26% had partial improvement, and only around 6% recovered fully.⁶
Here is the honest nuance, because it matters. The catastrophic blindness cases cluster around the nose, forehead, and glabella — together accounting for the large majority of reported cases — not the tear trough.⁶
So the realistic picture is this: under-eye filler's common problems are cosmetic and reversible (and hyaluronidase can dissolve hyaluronic acid filler when needed), while its catastrophic problems, though documented for the periorbital region, are concentrated elsewhere on the face. That is not a reason to be careless. It is a reason to insist on an injector who knows the anatomy cold — because the entire safety margin lives in their technique.
Tear-trough filler is the highest-stakes injection on the face.
"Non-invasive" is not the same as "safe"
The belief: if there's no needle, there's no real risk. The most dangerous word in this area is "non-invasive."
HIFU — high-intensity focused ultrasound — is widely marketed for "non-surgical eye lifts" and "non-invasive tightening" around the eyes. It works by focusing ultrasound energy at a set depth under the skin to heat tissue to roughly 60–70 °C, triggering collagen contraction and, later, new collagen.⁷ No needle, no cut, no downtime. It sounds inherently gentle.
Near the eye, it is not. Focused ultrasound energy aimed at the eyelid can pass through the lid and reach the structures of the eye itself, where the same heat that remodels collagen coagulates ocular proteins.
The published case reports are specific and serious: traumatic cataract requiring surgery, iris depigmentation and atrophy, anterior uveitis, corneal opacity, conjunctival haemorrhage, acute pressure spikes inside the eye, and visual acuity falling as low as 20/630.⁸ ⁹ ¹⁰
In one case the opacities in the lens formed in the exact shape of the device's focal point — direct physical proof that the energy reached the eye.⁸
Near the eye, "non-invasive" is the most dangerous word in the room.
Two facts make this worse, not better. First, almost every serious case occurred when protective eye shields were not used, or when the operator was not properly trained — meaning much of this harm is preventable, which is precisely why it should never happen. Second, the periorbital area responds less well to HIFU than the jaw, cheeks, and mid-face; the overall efficacy of facial HIFU is modest to begin with.⁷
So the eye area combines a weaker cosmetic response with the highest anatomical risk on the device's map — one of the least predictable benefit-to-risk profiles on the face.
If you are considering this: certified medical eye shields are non-negotiable, the device should have real-time ultrasound visualisation so the operator can see the depth they are treating, and even then, zero risk does not exist near the eye. (Our full medical guide to HIFU covers the contraindications in detail.)
When tired eyes aren't cosmetic at all
The belief: tired-looking eyes are a skin problem. Sometimes they are a medical one — and no cosmetic treatment will fix it.
This is the part the "eye rejuvenation" conversation almost always skips. A meaningful share of people who feel their eyes look perpetually tired, red, heavy, or irritated are not describing a pigment or volume problem. They are describing dry eye disease, very often driven by meibomian gland dysfunction — the tiny oil glands along the eyelid margin failing to keep the tear film stable. Symptoms often include burning, fluctuating vision, grittiness, irritation, watery eyes, and eye fatigue — and many readers will suddenly recognise themselves in that list.
Some "tired eyes" aren't a skin problem at all — they're a medical one.
It is strongly linked to the things modern life and modern bodies throw at the eye: screen time (which cuts your blink rate), contact lenses, environment, and — importantly — hormonal change.
Dry eye becomes markedly more common around and after menopause. The mechanism is well established: the meibomian and tear glands carry sex-hormone receptors, and the decline of androgens in particular reduces the quality of the oil that stops tears evaporating.¹¹ ¹²
The role of estrogen is genuinely contradictory in the research, and — counter to the common assumption — hormone replacement therapy does not reliably fix it, and in some reports makes it worse.¹² This is why "it's just dryness, use drops" and "it's just hormones, take HRT" are both too simple.
There is a real, evidence-backed crossover treatment here, and it comes from the aesthetic device world: intense pulsed light (IPL). A 2025 systematic review and meta-analysis pooling 13 randomised controlled trials found IPL improves dry-eye symptoms from meibomian gland dysfunction, with a generally favourable safety profile.¹³ The honest caveat, in the authors' own framing: the certainty of the evidence is moderate and the benefit is not yet firmly established. So: a real signal and a real mechanism — not yet a guarantee.
And the point here is bigger than any single device. If your eyes feel tired as well as look tired, your first appointment should be with someone who can examine the surface of your eye — not someone holding a syringe. No filler, no cream, no laser fixes a tear-film problem. Treating the wrong layer is how you can spend years, and a lot of money, chasing a "look" that has a medical cause sitting underneath it.
The regenerative frontier
The belief: it's biological and new, so it must work. Biology and proof are not the same thing.
Two categories dominate the "regenerative under-eye" conversation, and they sit at opposite ends of the evidence spectrum.
Polynucleotides (often marketed as salmon-DNA / PDRN injectables) are the more credible of the two for skin quality around the eye — early real-world data and consensus practice guidance exist, and the biological rationale is reasonable. "Early but plausible" is the fair summary. We looked at the actual PubMed evidence for PDRN in depth in our Salmon DNA in cosmetics analysis.
Exosomes are the cautionary tale. Consumer interest has surged, but at the time of writing no exosome product holds FDA approval for aesthetic use, and the systematic reviews that exist repeatedly note the same problem: the clinical studies are few, methodologically weak, and confounded by the fact that exosomes are almost always delivered with microneedling or laser — so you cannot tell whether you are measuring the exosome or the needle. We covered this across our two-part series (the evidence and the products). The pattern — fascinating biology, absent proof — is one this area should learn to recognise.
What actually helps — sorted by what you actually have
The single thread running through all of this is the one the marketing almost never tells you: match the treatment to the cause. Sorted that way, here is the realistic picture.
If it's pigment (brown, doesn't fade when you stretch the skin):
sun protection is non-negotiable groundwork. The most evidence-aligned topical actives work by interfering with melanin: niacinamide (which slows the transfer of pigment into skin cells),ᵃ vitamin C and azelaic acid (which suppress the pigment-making enzyme tyrosinase), retinoids, and arbutin or tranexamic acid. Two honest caveats: as single ingredients the effect is modest — one trial of 20% vitamin C improved constitutional under-eye pigment in only about a quarter of people ᵇ — and combination formulas consistently outperform any one active.ᶜ Certain pigment-specific lasers are the step up. Filler does nothing for this, and can worsen it.
If it's vascular (bluish, thin translucent skin):
the goal is improving skin thickness and quality, not adding volume in front of the vessels. Cautious, deep filler can sometimes mask a hollow that exposes the vessels — but superficial filler here is what creates the Tyndall problem.
If it's structural (a true hollow / shadow that flattens when you stretch the skin):
this is the one situation where tear-trough filler genuinely shines — for the right person, with the right injector. It is also where the anatomy demands the most respect.
If your eyes feel tired, not just look tired:
start by having the surface of your eye examined, before any cosmetic treatment. It is the step most people skip, and often the one that matters most.
And the honest counterweight to all the caution: done well, for the right cause, several of these treatments work beautifully. The aim here isn't to scare you off — it's to give you footing. Walking into a consultation able to say "I think mine are mostly pigment, with a small hollow — what would you actually recommend?" instead of "can you fix my dark circles?" changes the care you get. You'll already have done the part almost everyone skips.
You'll already have done the part almost everyone skips.
The takeaway
- Diagnose before you treat. Pigment, vessels, and hollows need different — sometimes opposite — treatments. The stretch test is a starting point.
- Filler is for hollows, not for tiredness. On pigment or thin vascular skin it can make things worse.
- Distrust "non-invasive" as a synonym for "safe" near the eye. HIFU here carries documented ocular risk for modest benefit.
- If your eyes feel tired, get the surface examined. Dry eye and meibomian gland dysfunction are medical, common around menopause, and untouched by cosmetics.
- "Biological and new" is not "proven." Polynucleotides: early but plausible. Exosomes: not yet.